Center for Targeted Therapeutics

靶向治疗中心

基本信息

批准号：
9794379
负责人：
IGOR B RONINSON
金额：
$ 223.5万
依托单位：
UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-07-10 至 2024-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9794379
关键词：
Address Alzheimer&apos s Disease Applications Grants Area Automobile Driving Award Biology Career Mobility Cellular biology Centers of Research Excellence Chemicals Collaborations Complement Core Facility Databases Development Developmental Biology Disease Drug Compounding Drug Design Economic Development Education Educational workshop Environment Equipment Faculty Financial Support Flow Cytometry Fostering Friends Funding Future Goals Grant Interdisciplinary Study Laboratories Malignant Neoplasms Medical Mentors Microscopy Mission Molecular Target Paper Pharmaceutical Preparations Pharmacotherapy Phase Pilot Projects Play Process Public Health Publishing Reporting Research Research Infrastructure Research Personnel Research Project Grants Research Support Resource Sharing Resources Scientist Senior Scientist Services Small Business Innovation Research Grant Small Business Technology Transfer Research South Carolina Structure Talents Technology Therapeutic Therapeutic Human Experimentation Training United States National Institutes of Health Universities Vision Work cancer genomics career development cellular targeting college common treatment drug discovery drug synthesis faculty mentor functional genomics high risk infrastructure development instrumentation interest meetings member multidisciplinary new therapeutic target next generation operation programs prototype recruit research and development senior faculty success targeted treatment tenure track

项目摘要

ABSTRACT The principal Phase II goal of the COBRE Center for Targeted Therapeutics (CTT) is to conduct vital research oriented at identifying novel drug targets and discovering new targeted drugs, while enhancing the career development and research competitiveness of Center investigators. Targeted therapeutics is a broad term for research that seeks to develop new and more effective classes of drugs against various diseases, by selectively aiming these drugs at molecular and cellular targets that play a key role in the disease. The area of Targeted Therapeutics has been chosen because of its societal impact, the emergence of common technologies driving therapeutics research in different disease areas, and the presence of a critical core of senior faculty with broad acumen and trans-disciplinary vision in Targeted Therapeutics at USC. During Phase I, junior investigators leading CTT research projects (target PIs) were awarded five R01s and several smaller grants, and pilot project recipients received two R01s and several other grants, for a total of close to $14 million. Four target PIs received promotion and tenure and almost 50 published papers acknowledged COBRE support. Three resource cores established by the CTT provided services to 64 different laboratories and organized training workshops and a new graduate course. To build upon the success of Phase I, we will pursue the following Specific Aims. Aim 1. Support high-impact research projects and assist junior scientists in Targeted Therapeutics in their professional development and competitiveness for NIH grants, in a collaborative and nurturing environment. Target junior faculty members include four highly promising scientists, each of whom will be mentored by two senior scientists with different areas of expertise relevant to their research. Aim 2. Establish sustainable research infrastructure through the further development of strategic Cores for Targeted Therapeutics research. The Center supports research cores in Functional Genomics, Drug Design and Synthesis, and Microscopy and Flow Cytometry. These cores will provide both specialized services and intellectual scientific support. Aim 3. Assure long-term development of the CTT by broadening collaborative networking, fostering continuous recruitment, supporting new faculty in Targeted Therapeutics, and supporting pilot research projects, with an emphasis on drug discovery and preparation for multi-investigator and SBIR/STTR grant applications. CTT will conduct regular meetings and seminars and promote external collaborations. CTT will participate in the recruitment of five new junior faculty members to USC and will continue working with the “graduated” target faculty, assuring that they continue to make important discoveries and win grants. Continued success of the CTT will make an impact on the public health, scientific education and economic development of the State.

抽象的 COBRE 靶向治疗中心 (CTT) 第二阶段的主要目标是进行重要研究致力于识别新的药物靶点和发现新的靶向药物，同时提升职业生涯中心研究人员的开发和研究竞争力是一个广义术语。研究旨在通过选择性地开发针对各种疾病的新的、更有效的药物类别这些药物针对在疾病中起关键作用的分子和细胞靶点。选择治疗方法是因为其社会影响、共同技术的出现推动不同疾病领域的治疗研究，以及具有广泛知识的高级教师的关键核心的存在南加州大学靶向治疗的敏锐性和跨学科视野在第一阶段，初级研究人员。领先的 CTT 研究项目（目标 PI）获得了 5 个 R01 和几项较小的资助以及试点项目受助者收到了两笔 R01 和几笔其他赠款，总共收到了四项目标 PI 近 1400 万美元。晋升和终身教职以及近 50 篇发表的论文承认 COBRE 的支持。 CTT 建立的机构为 64 个不同的实验室提供服务，并组织了培训讲习班和为了在第一阶段的成功基础上，我们将追求以下具体目标。目标 1. 支持高影响力的研究项目并协助靶向治疗领域的初级科学家在协作和培育的环境中，提高 NIH 拨款的专业发展和竞争力。目标初级教员包括四名非常有前途的科学家，每人将由两名具有与其研究相关的不同专业知识领域的资深科学家。目标 2. 通过进一步开发战略核心来建立可持续的研究基础设施该中心支持功能基因组学、药物设计和靶向治疗研究的核心。这些核心将提供专业服务和合成、显微镜和流式细胞术。智力科学支持。目标 3. 通过扩大协作网络、促进持续的合作，确保 CTT 的长期发展招聘、支持靶向治疗领域的新教师以及支持试点研究项目，重点关注多研究者和 SBIR/STTR 拨款申请的药物发现和准备。定期举行会议和研讨会并促进外部合作。CTT 将参与其中。南加州大学招聘五名新的初级教员，并将继续努力实现“毕业”目标教师，确保他们继续取得重要发现并赢得 CTT 的持续成功。将对国家的公共卫生、科学教育和经济发展产生影响。